ArticleClinical and experimental immunology1998
Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis.
Article in Clinical and experimental immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 81 citations in OpenAlex.
- Determination of the Predictive Roles and Potentially Pathogenic Antigen Epitopes of α-Enolase Related to the Development of Miscarriage in Females with Autoimmune Thyroiditis.International journal of molecular sciences · 2023Article
- Redox Control of the Immune Response in the Hepatic Progenitor Cell Niche.Frontiers in cell and developmental biology · 2020Article
- Absence of keratin 8 or 18 promotes antimitochondrial autoantibody formation in aging male mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.Journal of proteome research · 2013Article
- Biliary atresia: cellular dynamics and immune dysregulation.Seminars in pediatric surgery · 2012Review
- α-enolase autoantibodies cross-reactive to viral proteins in a mouse model of biliary atresia.Gastroenterology · 2010Article
- Chemical unfolding of enolase from Saccharomyces cerevisiae exhibits a three-state model.The protein journal · 2010Article
- The immunobiology of primary sclerosing cholangitis.Seminars in immunopathology · 2009Review
- Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?Clinical reviews in allergy & immunology · 2009Review
- Autoantibodies in primary sclerosing cholangitis.World journal of gastroenterology · 2008Review
- The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy.Journal of clinical immunology · 2007Article
- Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases.Clinical reviews in allergy & immunology · 2005Review
- Review
- IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.Clinical and experimental immunology · 2003Article
- Article
- Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy.Clinical and experimental immunology · 2001Article
- Primary sclerosing cholangitis.Clinical reviews in allergy & immunology · 2000Review
- Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN).Clinical and experimental immunology · 1999Article
- Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?Clinical and experimental immunology · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. Recent studies have shown that genetic factors and both cellular and humoral immunological abnormalities are important in the pathogenesis of PSC. The most prominent autoantibodies in PSC are anti-neutrophil cytoplasmic antibodies (ANCA). The autoepitopes of ANCA in PSC are not well defined. The aim of this study was to identify corresponding ANCA autoantigens in patients with PSC. A biochemical approach with enrichment and partial purification of soluble neutrophil proteins, detection of autoantibodies by Western blot and partial amino acid sequencing were used. Two new autoantigen/autoantibody systems in patients with PSC were detected: catalase and alpha-enolase. The presence of catalase autoantibodies in 9/15 (60%) and alpha-enolase autoantibodies in 4/15 (27%) was confirmed by ELISA and Western blot. Furthermore, we showed immunoreactions of PSC sera with human biliary epithelial cells, showed the reduction of fluorescence in anti-catalase absorption experiments and observed partial co-localization of anti-catalase antibodies and PSC sera in double-staining experiments on biliary epithelial cells. The anti-catalase antibody-positive PSC patients had a more severe course of disease with a significantly higher alkaline phosphatase compared with the anti-catalase-negative PSC patients (P < 0.06). All ulcerative colitis control sera were anti-catalase antibody-negative. The identified antigens catalase and alpha-enolase can partly explain the ANCA fluorescence on ethanol-fixed and formaldehyde-fixed granulocytes in patients with PSC. Catalase is an important anti-oxidant enzyme and prevents cell damage from highly reactive oxygen-derived free radicals. Catalase autoantibodies might play a pathogenic role in patients with PSC. Our findings support the hypothesis that oxidative stress is one of the pathogenic mechanisms in patients with PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.